Chemiluminescence kit for the detection of Jo-1 antibodies in human serum or plasma.

Coming soon
Catalog Number: CL-Jo1050
Size: 50 tests
Regulatory status: CE IVD
Clinical topic: Immunology & Autoimmune Diseases
  • Detection of anti-Jo-1 antibodies, IgG class
  • Evaluating patients with signs and symptoms compatible with a connective tissue disease, especially muscle pain and limb weakness, concomitant pulmonary signs and symptoms, Raynaud phenomenon, and arthritis
  • Testing for antibodies to Jo 1 is not useful in patients with a negative test for antinuclear antibodies
  • Intended for human serum and plasma
  • Recombinant Jo-1 antigen used as the antigen

Jo-1 antigen is a histidyl-tRNA synthetase enzyme localized mainly in the cytoplasm. It is a member of the amino acyl-tRNA synthetase family of enzymes found in all nucleated cells. Anti-Jo-1 antibodies are highly specific for myositis. They are associated with polymyositis (20-40%). Less frequently, these antibodies are also found in dermatomyositis and myositis related to other connective tissue systemic diseases.

Anti-Jo-1 antibodies occur in up to 50% of patients with interstitial pulmonary fibrosis and symmetrical polyarthritis. More than 70% of patients positive for Jo-1 antibodies have interstitial lung disease. The anti-Jo-1 antibodies level corresponds with the disease activity.

The antisynthetase syndrome comprises presence of anti-Jo-1 antibodies, myositis, interstitial lung disease, rheumatoid arthritis, or Raynaud's phenomenon. The disease manifestation differs depending on the type of anti-synthetase antibody (most often anti-Jo-1 antibody).

Antigen Used: Recombinant Jo-1 antigen.

Technical specifications

Technical data
Related Products

Technical data

Assay stability (on board)30 days
Sample matrix Serum, Plasma
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic particles, calibrators
Complementary productsWash buffer, Anchor® Tips, Stackable cuvettes, Trigger solutions


References to CLIA Jo-1

  • Targoff IN. Autoantibodies in polymyositis. Rheum Dis Clin North Am. 1992 May;18(2):455-82. PMID: 1378227.
    See more on PubMed
  • Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-Jo-1 antibodies. Autoimmunity. 2005 Feb;38(1):73-8. doi: 10.1080/08916930400022640. PMID: 15804708.
    See more on PubMed
  • Mileti LM, Strek ME, Niewold TB, Curran JJ, Sweiss NJ. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol. 2009 Aug;15(5):254-5. doi: 10.1097/RHU.0b013e3181b0e910. PMID: 19590436; PMCID: PMC3380442.
    See more on PubMed
  • Jiang M, Dong X, Zheng Y. Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies. Medicine (Baltimore). 2021 May 14;100(19):e25816. doi: 10.1097/MD.0000000000025816. PMID: 34106621; PMCID: PMC8133147.
    See more on PubMed
  • de Andrade VP, De Souza FHC, Behrens Pinto GL, Shinjo SK. The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis. Adv Rheumatol. 2021 Feb 19;61(1):12. doi: 10.1186/s42358-021-00171-x. PMID: 33608062.
    See more on PubMed
  • Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):472-8. doi: 10.1136/jnnp.68.4.472. PMID: 10727483; PMCID: PMC1736872.
    See more on PubMed

Do you want to learn more?
We're here for you

Please fill in
all fields
marked *
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Find out more here.